1. Home
  2. TLSA vs AIRG Comparison

TLSA vs AIRG Comparison

Compare TLSA & AIRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

N/A

Current Price

$1.14

Market Cap

145.1M

Sector

Health Care

ML Signal

N/A

Logo Airgain Inc.

AIRG

Airgain Inc.

N/A

Current Price

$4.25

Market Cap

67.6M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
TLSA
AIRG
Founded
2013
1995
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Radio And Television Broadcasting And Communications Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
145.1M
67.6M
IPO Year
2017
2016

Fundamental Metrics

Financial Performance
Metric
TLSA
AIRG
Price
$1.14
$4.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$7.97
★ $8.88
AVG Volume (30 Days)
★ 545.0K
29.7K
Earning Date
05-01-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 31.65
EPS
★ N/A
N/A
Revenue
N/A
★ $51,779,000.00
Revenue This Year
N/A
$9.20
Revenue Next Year
N/A
$17.61
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.76
$3.00
52 Week High
$2.33
$7.66

Technical Indicators

Market Signals
Indicator
TLSA
AIRG
Relative Strength Index (RSI) 59.09 N/A
Support Level $0.90 N/A
Resistance Level $1.20 N/A
Average True Range (ATR) 0.09 0.00
MACD 0.02 0.00
Stochastic Oscillator 94.69 0.00

Price Performance

Historical Comparison
TLSA
AIRG

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

About AIRG Airgain Inc.

Airgain Incs a provider of advance wireless connectivity solutions. It is focused on delivering high-performance, cost-effective, and energy-efficient wireless solutions that enable rapid market deployment. It mission is to connect the world through integrated, and optimized wireless solutions. Companies' diverse product portfolio serves three primary markets: enterprise, automotive, and consumer. While historically recognized for high-performance radio frequency (RF) components, Airgain is increasingly delivering integrated, system-level connectivity solutions that combine hardware, software, and cloud management. The enterprise market demands reliable wireless access across diverse settings, including smart cities, campuses, stadiums, transportation hubs, utilities, buildings suburbs.

Share on Social Networks: